Zacks Investment Research lowered shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) from a buy rating to a hold rating in a research report released on Thursday.

According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. “

ABEO has been the topic of a number of other research reports. SunTrust Banks, Inc. assumed coverage on Abeona Therapeutics in a report on Wednesday, November 8th. They issued a buy rating and a $26.00 target price on the stock. BidaskClub lowered Abeona Therapeutics from a buy rating to a hold rating in a report on Wednesday, August 2nd. Maxim Group set a $35.00 target price on Abeona Therapeutics and gave the company a buy rating in a report on Monday, November 20th. Royal Bank Of Canada assumed coverage on Abeona Therapeutics in a report on Thursday, September 14th. They issued an outperform rating and a $23.00 target price on the stock. Finally, Cantor Fitzgerald reissued a buy rating and issued a $21.00 target price on shares of Abeona Therapeutics in a report on Friday, October 6th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $26.10.

Shares of Abeona Therapeutics (NASDAQ ABEO) opened at $16.75 on Thursday. Abeona Therapeutics has a 52 week low of $4.05 and a 52 week high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.22 million. research analysts expect that Abeona Therapeutics will post -0.6 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in ABEO. Vanguard Group Inc. grew its holdings in Abeona Therapeutics by 11.2% during the second quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock worth $6,922,000 after acquiring an additional 108,730 shares during the period. State Street Corp acquired a new position in Abeona Therapeutics during the second quarter worth $1,900,000. Northern Trust Corp grew its holdings in Abeona Therapeutics by 406.3% during the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock worth $1,649,000 after acquiring an additional 206,775 shares during the period. Point72 Asset Management L.P. acquired a new position in Abeona Therapeutics during the third quarter worth $3,527,000. Finally, Geode Capital Management LLC grew its holdings in Abeona Therapeutics by 2.4% during the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock worth $980,000 after acquiring an additional 4,588 shares during the period. 36.34% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Abeona Therapeutics Inc. (ABEO) Downgraded by Zacks Investment Research” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/abeona-therapeutics-inc-abeo-downgraded-by-zacks-investment-research/1726776.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.